Recommendations for statin therapy in the elderly;Empfehlungen zur statintherapie im alter. Daten und konsensus

Internist

Volumn 45, Issue 9, 2004, Pages 1053-1062

  Doser S ^a   Marz W ^j   Reinecke, M F ^b   Ringleb, P ^a   Schultz, A ^a   Schwandt, P ^c   Becker, H J ^d   Bonner G ^e   Buerke, M ^f   Diener, H C ^g   Gohlke, H ^h   Keil, U ⁱ   Ringelstein, E B ⁱ   Steinmetz, A ^k   Gladisch, R ^a   Wehling, M ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Arteriosklerose Praventions Institut   (Germany)

^d Deutsche Herzstiftung eV   (Germany)

^e Rehaklinik Lazariterhof   (Germany)

^f MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^g UNIVERSITY OF DUISBURG ESSEN   (Germany)

^h Westfalische Wilhelms Univ Munster ^*  (Germany)

ⁱ UNIVERSITY OF MÜNSTER   (Germany)

^j MEDICAL UNIVERSITY OF GRAZ   (Austria)

^k UNIVERSITY OF BONN   (Germany)

more..

Author keywords

Efficacy; Elderly patient; Hypercholesterolemia; Statins

Indexed keywords

AMIODARONE; ATORVASTATIN; CIMETIDINE; CYCLOSPORIN A; DIGOXIN; DILTIAZEM; ERYTHROMYCIN; ETHINYLESTRADIOL; FLUINDOSTATIN; FLUVOXAMINE; GEMFIBROZIL; ITRACONAZOLE; METRONIDAZOLE; MEVINOLIN; MIBEFRADIL; NICOTINE; NORETHISTERONE; OMEPRAZOLE; PAROXETINE; PHENYTOIN; PRAVASTATIN; PROPAFENONE; PROTEINASE INHIBITOR; QUINIDINE; RANITIDINE; SIMVASTATIN; STATIN; THIORIDAZINE; UNINDEXED DRUG; WARFARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

AGED; AGING; CARDIOVASCULAR RISK; DEMENTIA; DEPRESSION; DRUG EFFICACY; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; LIFE EXPECTANCY; LIPID BLOOD LEVEL; PATIENT COMPLIANCE; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; CORONARY ARTERY DISEASE; DRUG UTILIZATION; FEMALE; FORECASTING; GERMANY; MALE; MIDDLE AGED; MORTALITY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; CORONARY DISEASE; DRUG UTILIZATION; FEMALE; FORECASTING; GERMANY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIFE EXPECTANCY; MALE; MIDDLE AGED; PATIENT COMPLIANCE; TREATMENT OUTCOME;

EID: 16644386857     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-004-1268-6     Document Type: Review

References (38)

1. Chobanian AV, Bakris GL, Black HR et al. (2003) Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42:1206
2. Athyros VG, Papageorgiou AA, Mercouris BR et al. (2002) Treatment with atorvastatin to the National Cholesterol Educational Program goal versus "usual" care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 18:220-228
3. Bartlett C, Davey P, Dieppe P et al. (2003) Women, older persons, and ethnic minorities: factors associated with their inclusion in randomised trials of statins 1990 to 2001. Heart 89:327-328(A)
4. Benner JS, Glynn RJ, Mogun H et al. (2002) Long-term persistence in use of statin therapy in elderly patients. JAMA 288:455-461
5. DeWilde S, Carey IM, Bremner SA et al. (2003) Evolution of statin prescribing 1994-2001: a case of agism but not of sexism? Heart 89:417-421
6. Ford I, Blauw GJ, Murphy MB et al. (2002) A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): screening experience and baseline characteristics. Curr Controll Trials Cardiovasc Med 3:8
7. Glaeske G, Jahnsen K (2003) GEK-Arzneimittel-Report, Schriftenreihe zur Gesundheitsanalyse, Band 25. Asgard Vlg, St. Augustin, S 98-104
8. Gohlke H, Kübler W, Mathes P et al. (2003) Positionspapier zur Primärprävention kardiovaskulärer Erkrankungen. Z Kardiol 92:S22-S24
9. Hammerness P, Basch E, Ulbricht C et al. (2003) St John's wort: a systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics 44:271-282
10. Held K (2002) Prävention und Therapie im Alter. Jahresempfehlung 2002 der Nationalen Herz-Kreislauf-Konferenz (NHKK). Dtsch Med Wochenschr 127:1039-1041
11. Jackevicius CA, Mamdani M, Tu JV (2002) Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 288:462-467
12. Jenni D, Osterwalder R, Osswald S et al. (2001) Evidence for age-based rationing in a Swiss university hospital. Swiss Med Wkly 131:630-634
13. Kannel WB, Vokonas PS (1992) Demographics of the prevalence, incidence and management of coronary heart disease in the elderly and in women. Ann Epidemiol 2:5-14(A)
14. Kannel WB (2002) The Framingham study: historical insight on the impact of cardiovascular risk factors in men versus women. J Gend Specif Med 5:27-37
15. Majeed A, Moser K, Maxwell R (2000) Age, sex and practice variations in the use of statins in general practice in England and Wales. J Public Health Med 22:275-279
16. ALLHAT - Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT) JAMA 288:2998-3007
17. März W, Wollschläger H, Klein G et al. (1999) Safety of low-density lipoprotein cholesterol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the target tangible trial) Am J Cardiol 84:7-13
18. Miettinen TA, Pyörälä K, Olsson AG et al. (1997) Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 96:4211-4218
19. Violi F, Mecheletta F, Inliano L; MRC/BHF Heart Protection Study (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7-22
20. Mungall MM, Gaw A, Shepherd J (2003) Statin therapy in the elderly. Does it make good clinical and economic sense? Drugs Aging 20:263-275
21. Mutschler E, Geisslinger G, Kroemer HK, Schäfer-Korting M (2001) Arzneimittelwirkungen. 8. Aufl. Wissenschaftl. Verlagsgesellschaft, Stuttgart
22. Pasternak RC, Smith SC Jr., Bairey-Merz CN et al. (2002) ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 105:1024-1028
23. Phillips PS, Haas RH, Bannykh S et al. (2002) Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 137:581-585(A)
24. Sacks FM, Pfeffer MA, Moye LA et al. (1996) For the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med 335:1001-1009
25. Schwandt P, Richter W, Parhofer K (2001) Handbuch der Fettstoffwechselstörungen, 2. Aufl. Schattauer, Stuttgart
26. Schwartz JS (1999) Comparative economic data regarding lipid-lowering drugs. Am Hearth J 137: S97-S104
27. Sever PS, Dahlof B, Poulter NR et al. (2003) For the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average and lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid-Lowering-Arm (ASCOT-LLA): a multicentre randomised trial. Lancet 361:1149-1158
28. Shepherd J, Blauw GJ, Murphy MB et al. (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360:1623-1630
29. Shepherd J, Gaw A, West of Scotland Coronary Prevention Study Group (2002) The anatomy of clinical trial. The West of Scotland Coronary Prevention Study. Med Princ Parct 11 [Suppl 2]:17-30(A)
30. Sica DA, Gehr TW (2002) Rhabdomyolysis and statin therapy: relevance to the elderly. Am J Geriatr Cardiol 11:28-55(A)
31. Simpson E, Beck C, Richard H et al. (2003) Drug prescription after acute myocardial infarction: dosage, compliance, and persistance. Am Heart J 14S:438-444
32. Staffa JA, Chang J, Green L (2002) Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 346:539-540
33. Stamler J, Wentworth D, Neaton JD (1986) Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 256:2823-2828
34. Völler H, Klein G, Gohlke H et al. (2000) Sekundärprä vention Koronarkranker nach stationärer Rehabilitation. Dtsch Med Wochenschr 125:1457-1461
35. Williams DD, Feely J (2002) Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 41:343-370
36. Sachverständigenrat für konzertierte Aktion im Gesundheitswesen. Bedarfsgerechtigkeit und Wirtschaftlichkeit. Band III: Über-, Unter- und Fehlversorgung. Gutachten 2000/2001, S 23
37. The LIPID Study Group (2002) Long-term effectiveness and safety of pravastatin on 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 359:1379-1387
38. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report National Cholesterol Education Program National Heart, Lung, and Blood Institute, National Institutes of Health NIH Publication No. 02-5215 September 2002